Curis has treated the first patient in a Phase I combination trial of CUDC-101, a first-in-class treatment that simultaneously inhibits histone deacetylase (HDAC), Histone Deacetylase 6 drugs development Market and epidermal growth factor receptor (EGFR). The purpose of the Phase I combination trial, which is open-label and dose-escalating, is to test CUDC-101 in approximately 15 to 25 patients...